These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19004724)

  • 21. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
    Di Leo A; Isola J
    Clin Breast Cancer; 2003 Aug; 4(3):179-86. PubMed ID: 14499010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
    Ooe A; Kato K; Noguchi S
    Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
    Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
    Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
    Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F
    Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.
    Hamel S; Bouchard A; Ferrario C; Hassan S; Aguilar-Mahecha A; Buchanan M; Quenneville L; Miller W; Basik M
    Breast Cancer Res Treat; 2010 Feb; 120(1):47-57. PubMed ID: 19301121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer.
    Dimas-González J; Maldonado-Lagunas V; Díaz-Chávez J; López-Arellano ME; Muñoz-Camacho J; Terán-Porcayo MA; Lagunas-Martínez A
    Oncol Rep; 2017 May; 37(5):3026-3036. PubMed ID: 28393224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms].
    Gai XD; Li GL; Huang JZ; Xue HJ; Wang D
    Ai Zheng; 2006 Aug; 25(8):954-9. PubMed ID: 16965674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allelic imbalance at the HER2/TOP2A locus in breast cancer.
    Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH
    Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    Oakman C; Moretti E; Sotiriou C; Viale G; Di Leo A
    J Natl Cancer Inst; 2009 Dec; 101(24):1735-6; author reply 1736-7. PubMed ID: 19893008
    [No Abstract]   [Full Text] [Related]  

  • 34. HER-2 and topoisomerase II as predictors of response to chemotherapy.
    Pritchard KI; Messersmith H; Elavathil L; Trudeau M; O'Malley F; Dhesy-Thind B
    J Clin Oncol; 2008 Feb; 26(5):736-44. PubMed ID: 18258981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive value of HER2 in breast cancer.
    Piccart M; Lohrisch C; Di Leo A; Larsimont D
    Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
    Bartlett JM; McConkey CC; Munro AF; Desmedt C; Dunn JA; Larsimont DP; O'Malley FP; Cameron DA; Earl HM; Poole CJ; Shepherd LE; Cardoso F; Jensen MB; Caldas C; Twelves CJ; Rea DW; Ejlertsen B; Di Leo A; Pritchard KI
    J Clin Oncol; 2015 May; 33(15):1680-7. PubMed ID: 25897160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anthracyclines are a critical component of adjuvant chemotherapy regimens for high-risk early breast cancer.
    Morris PG; Hudis CA; Dang CT
    Oncology (Williston Park); 2011 Feb; 25(2):134-5, 138, 140. PubMed ID: 21456384
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.